title: [ANMCO/SICI-GISE document on antiplatelet therapy in patients with acute coronary syndrome].
abstract: Antiplatelet therapy is the cornerstone of the pharmacologic management of patients with acute coronary syndrome (ACS). Over the last years, several studies have evaluated old and new oral or intravenous antiplatelet agents in ACS patients. In particular, research was focused on assessing superiority of two novel platelet ADP P2Y12 receptor antagonists (i.e., prasugrel and ticagrelor) over clopidogrel. Several large randomized controlled trials have been undertaken in this setting and a wide variety of prespecified and post-hoc analyses are available that evaluated the potential benefits of novel antiplatelet therapies in different subsets of patients with ACS. The aim of this document is to review recent data on the use of current antiplatelet agents for in-hospital treatment of ACS patients. For each drug or class of drugs, strong evidence and/or areas of uncertainty that warrant further research are highlighted by examining 10 subgroups of patients with ACS.
authors: Leonardo
authors: L
authors: De Luca
authors: Leonardo
authors: L
authors: Bolognese
authors: Marco
authors: M
authors: Valgimigli
authors: Roberto
authors: R
authors: Ceravolo
authors: Gian Battista
authors: GB
authors: Danzi
authors: Emanuela
authors: E
authors: Piccaluga
authors: Serena
authors: S
authors: Rakar
authors: Alberto
authors: A
authors: Cremonesi
authors: Francesco Maria
authors: FM
authors: Bovenzi
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*
chemical_list: D010975:Platelet Aggregation Inhibitors